Nektar Therapeutics Common Stock (NASDAQ: NKTR) last traded at $39.84, down 3.23% on the session. The quote above updates while this page is open; the figures below are drawn from Nektar Therapeutics Common Stock’s own filings and are restated only when a new one is published.
Nektar Therapeutics Common Stock trades on NASDAQ under the ticker NKTR. Its market capitalisation is $1.36 billion.
Valuation measures for Nektar Therapeutics Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $1.36B |
|---|---|
| Enterprise value | $1.51B |
| Price / sales | 24.92 |
| Price / book | 1.51 |
| Beta | 1.00 |
Trailing-twelve-month figures tagged in Nektar Therapeutics Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $54.59M |
|---|---|
| Net income (TTM) | -$157.13M |
| EPS (TTM) | -$6.21 |
| Operating margin | -257.80% |
| Return on equity | -17.40% |
| Cash | $39.27M |
Range and volume for NKTR over the past 52 weeks.
| 52-week high | $109.00 |
|---|---|
| 52-week low | $33.40 |
| Volume | 955.0K |
| Average volume | 1.08M |
| Previous close | $41.17 |
Invest a chosen dollar amount in Nektar Therapeutics Common Stock with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell NKTR.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.